Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
CA Luke, MYS Moosa, TM Esterhuizen, SE Knight, S Saman & A Ross. (2014) Lactic acidosis, risk factors and predictive laboratory markers: a nested case control study in South Africa. South African Family Practice 56:1, pages 63-68.
Read now
Read now
Adrian Curran & Esteban Ribera. (2011) From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. Expert Opinion on Drug Safety 10:3, pages 389-406.
Read now
Read now
Anne Maagaard & Dag Kvale. (2009) Long term adverse effects related to nucleoside reverse transcriptase inhibitors: Clinical impact of mitochondrial toxicity. Scandinavian Journal of Infectious Diseases 41:11-12, pages 808-817.
Read now
Read now
Articles from other publishers (21)
Willem Daniel Francois Venter, Andrew Kambugu, Matthew F. Chersich, Stephen Becker, Andrew Hill, Natasha Arulappan, Michelle Moorhouse, Mohammed Majam, Godspower Akpomiemie, Simiso Sokhela, Selvamuthu Poongulali, Charles Feldman, Chris Duncombe, David H. Brown Ripin, Alinda Vos & Nagalingeswaran Kumarasamy. (2019) Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 80:2, pages 224-233.
Crossref
Crossref
Nombulelo Magula & Martin Dedicoat. (2015) Low dose versus high dose stavudine for treating people with HIV infection. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Sherwin K. B. Sy, Steve Innes, Hartmut Derendorf, Mark F. Cotton & Bernd Rosenkranz. (2014) Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily. Antimicrobial Agents and Chemotherapy 58:2, pages 1084-1091.
Crossref
Crossref
Steve Innes, Mark F Cotton, Richard Haubrich, Maria M Conradie, Margaret van Niekerk, Clair Edson, Helena Rabie, Sonia Jain, Xiaoying Sun, Ekkehard W Zöllner, Stephen Hough & Sara H Browne. (2012) High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatrics 12:1.
Crossref
Crossref
Nittaya Phanuphak, Jintanat Ananworanich, Nipat Teeratakulpisarn, Tanate Jadwattanakul, Stephen J Kerr, Nitiya Chomchey, Piranun Hongchookiat, Pornpen Mathajittiphun, Suteeraporn Pinyakorn, Patcharawee Rungrojrat, Pairoa Praihirunyakit, Mariana Gerschenson, Praphan Phanuphak, Victor Valcour, Jerome H Kim & Cecilia Shikuma. (2012) A 72-Week Randomized Study of the Safety and Efficacy of a Stavudine to Zidovudine Switch at 24 Weeks Compared to Zidovudine or Tenofovir Disoproxil Fumarate when Given with Lamivudine and Nevirapine. Antiviral Therapy 17:8, pages 1521-1531.
Crossref
Crossref
Mélanie Prague, Daniel Commenges, Julia Drylewicz & Rodolphe Thiébaut. (2012) Treatment Monitoring of HIV‐Infected Patients based on Mechanistic Models. Biometrics 68:3, pages 902-911.
Crossref
Crossref
Meera Pahuja, Anneke Grobler, Marshall J Glesby, Farina Karim, Gary Parker, Sizwe Gumede & Kogieleum Naidoo. (2012) Effects of a Reduced Dose of Stavudine on the Incidence and Severity of Peripheral Neuropathy in HIV-Infected Adults in South Africa. Antiviral Therapy 17:4, pages 737-743.
Crossref
Crossref
Mhairi Maskew, Daniel Westreich, Matthew P Fox, Thapelo Maotoe & Ian M Sanne. (2012) Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV‐infected adults initiating HAART in South Africa. Journal of the International AIDS Society 15:1, pages 13-13.
Crossref
Crossref
Mar Pujades-Rodríguez, Emmanuelle Dantony, Loretxu Pinoges, René Ecochard, Jean-François Etard, Esther Carrillo-Casas & Elisabeth Szumilin. (2011) Toxicity Associated with Stavudine Dose Reduction from 40 to 30 mg in First-Line Antiretroviral Therapy. PLoS ONE 6:11, pages e28112.
Crossref
Crossref
Selwyn J. Hurwitz & Raymond F. Schinazi. (2011) In silico study supports the efficacy of a reduced dose regimen for stavudine. Antiviral Research 92:2, pages 372-377.
Crossref
Crossref
Amandine Cournil, Mathilde Coudray, Charles Kouanfack, Claudine Ntsama Essomba, Clément Auguste Djouatsa Tonfack, Magloire Biwolé-Sida, Eric Delaporte, Kirsten Bork & Christian Laurent. (2010) Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Antiviral Therapy 15:7, pages 1039-1043.
Crossref
Crossref
Andrew Hill. (2010) d4T: keep it or abandon it?. Asian Biomedicine 4:4, pages 541-546.
Crossref
Crossref
A. Maagaard & D. Kvale. (2009) Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?. Journal of Antimicrobial Chemotherapy 64:5, pages 901-909.
Crossref
Crossref
Anissa Igoudjil, Julie Massart, Karima Begriche, Véronique Descatoire, Marie-Anne Robin & Bernard Fromenty. (2008) High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicology in Vitro 22:4, pages 887-898.
Crossref
Crossref
Richard A. Murphy, Henry Sunpath, Daniel R. Kuritzkes, Francois Venter & Rajesh T. Gandhi. (2007) Antiretroviral Therapy–Associated Toxicities in the Resource‐Poor World: The Challenge of a Limited Formulary. The Journal of Infectious Diseases 196:s3, pages S449-S456.
Crossref
Crossref
Pablo Labarga & Vicente Soriano. (2007) Estavudina en el tratamiento antirretroviral. Medicina Clínica 129:10, pages 375-376.
Crossref
Crossref
Enric Pedrol, Teodoro Martín, Miguel Angel del Pozo, Juan Flores, José Sanz, José A. Cartón, Juan-José Jusdado, Piedad Arazo, Esteve Ribera & Elisabet Deig. (2007) Impacto de la reducción de dosis de estavudina en su perfil de eficacia/seguridad en pacientes con infección por el virus de la inmunodeficiencia humana inmunológica y virológicamente estables. Medicina Clínica 129:10, pages 361-365.
Crossref
Crossref
Ulrich Spengler. 2007. Drug-Induced Liver Disease, Second Edition. Drug-Induced Liver Disease, Second Edition
567
591
.
Anissa Igoudjil, Adjé Abbey-Toby, Karima Begriche, Alain Grodet, Karine Chataigner, Gilles Peytavin, Mustapha Maachi, Marion Colin, Marie-Anne Robin, Philippe Lettéron, Gérard Feldmann, Dominique Pessayre & Bernard Fromenty. (2006) High Doses of Stavudine Induce Fat Wasting and Mild Liver Damage without Impairing Mitochondrial Respiration in Mice. Antiviral Therapy 12:3, pages 389-400.
Crossref
Crossref
Ana Milinkovic, Esteban Martinez, Sonia López, Elisa De Lazzari, Oscar Miró, Sergi Vidal, José L Blanco, Gloria Garrabou, Montserrat Laguno, Joan A Arnaiz, Agathe Leon, Maria Larrousse, Montserrat Lonca, Josep Mallolas & José M Gatell. (2006) The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antiviral Therapy 12:3, pages 407-416.
Crossref
Crossref
Geneviève ChêneBahia AmellalGaëlle PédronoKarine GourlainCorinne RancinanValérie JournotLaurent CottePierre PalmerNathalie De CastroVincent CalvezJean-Michel Molina. (2007) Changes in the Peripheral Blood mtDNA Levels in Naive Patients Treated by Different Nucleoside Reverse Transcriptase Inhibitor Combinations and Their Association with Subsequent Lipodystrophy. AIDS Research and Human Retroviruses 23:1, pages 54-61.
Crossref
Crossref